28 results about "Anti metastasis" patented technology

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The present invention discloses a calcium carbonate-conjugated polymer composite nanoparticle with anti-tumor and anti-metastasis effects and its application. The nanoparticles rupture and decompose in the weakly acidic microenvironment of the tumor, releasing the conjugated polymer and a large amount of Ca 2+ The conjugated polymer can generate reactive oxygen species or heat energy to kill tumor cells under light. In addition, reactive oxygen species can also put tumor cells in a state of high oxidative stress, causing mitochondrial dysfunction and desensitization of calcium ion-related channels, causing intracellular "calcium overload" and inducing tumor cell death. These multiple effects make the nanoparticles highly effective in cancer treatment. Extracellular Ca 2+ Increased levels can enhance the adhesion between tumor cells by regulating the morphology of cadherin, thereby inhibiting tumor cell migration. In this invention, the calcium carbonate-conjugated polymer composite nanoparticles have excellent anti-tumor and anti-metastasis effects, providing a new approach for the comprehensive treatment of cancer.

An embodiment of the present invention relates to: a cancer antigen peptide nanostructure comprising an assembly of cancer antigen peptides conjugated with deoxycholic acid; a method for preparing same; and use thereof. The inventors of the present invention confirmed that the nanostructure of the present invention effectively stimulates the maturation of dendritic cells, migrates to lymph nodes, and activates T cells. Also, in a cancer cell model, significant infiltration of cytotoxic T lymphocytes into primary tumors was observed, and an anti-metastatic effect was confirmed. Therefore, the nanostructure according to the present invention can be effectively used as a promising immunotherapy platform that can be applied to various intractable cancers.

The invention discloses application of HSF1A in preparation of a medicine for resisting lung cancer metastasis, and relates to the technical field of anti-tumor medicines. It is found for the first time that HSF1A can be used for inhibiting non-small cell lung cancer metastasis. The HSF1A is specifically combined with a CCT1 subunit ATPase structural domain of a TRIC / CCT compound, so that the protein folding function of the TRIC / CCT compound is interfered, and three key transfer promoting signal channels including YAP, STAT3 and mTOR are inhibited at the same time. In a pulmonary metastatic tumor model constructed by mouse tail intravenous injection, the formation of pulmonary metastatic tumor is obviously reduced by the HSF1A, and the fact that the HSF1A also has strong anti-metastatic capability in an in-vivo environment is proved; the safety is high, and the development and utilization prospects are good. The invention not only provides a new application of the HSF1A, but also provides a new thought and method for adjuvant therapy of cancers.

The present invention provides a derivative having a desloratadine tetravalent platinum structure, a preparation method, and a use thereof. The compound having a desloratadine tetravalent platinum structure is shown in general formula (I), #imgabs0# wherein #imgabs1# is selected from cisplatin or oxaliplatin; L is hydroxyl or #imgabs2#. The desloratadine tetravalent platinum compound of the present invention has good anti-tumor proliferation activity and a good therapeutic effect on metastatic malignant tumors; it can effectively inhibit the tumor epithelial-mesenchymal transition (EMT) process and effectively activate tumor immune response, and can be used to prepare anti-tumor drugs, especially providing a new direction for the research and development of anti-metastatic malignant tumor drugs.

Systems and methods for radiation therapy for cancerous tumors using biocompatible quantum dots to provide radiation dose enhancement and resistance to metastasis are described. In an aspect, a method for radiation therapy treatment of cancer cells, includes, but is not limited to, preparing a radiosensitizer fluid, the radiosensitizer fluid including a plurality of biocompatible quantum dots; introducing the radiosensitizer fluid to cancer cells; and irradiating the cancer cells with the radiosensitizer fluid to promote generation of reactive oxygen species and inhibit radiation-induced enhancement of cell-migration.

The invention relates to the technical field of biological medicines, in particular to application of four micro RNAs (Ribonucleic Acid) of miR-92a, miR-25, miR-30d and miR-30c and inhibitors targeting the four micro RNAs to preparation of medicines for resisting metastasis of multiple cancer species such as breast cancer, colorectal cancer and melanoma. When the nucleic acid inhibitor anti-agomirs targeting at least one of a set consisting of miR-92a, miR-25, miR-30d and miR-30c is used for treating metastasis of multiple cancer species, the anti-metastasis effect is remarkable, the universality is high, and the nucleic acid inhibitor anti-agomirs can show a strong inhibition effect in three different tumor metastasis models of breast cancer, colorectal cancer and melanoma; especially, when the four inhibitors are combined for use, the synergistic effect is prominent, the colorectal cancer liver metastasis load can be reduced by 90% or above, the breast cancer metastasis rate is reduced by 80% or above, the melanoma metastasis inhibition rate is 65% or above, and the composition is suitable for treatment of multi-cancer metastasis.

The present invention conveys a fractionation method to isolate different bioactive Phytocannabinoids by solid phase extraction using HP-20 resins and one step method to synthesize C- and O-β-D-glycoside derivatives of Cannabinoid by using a β-D-glucose donor (O-Glycosyl trichloroacetimidate donor) to obtain glycosidic derivatives. The novel C-glycosides of Cannabinoids displayed significant anti-proliferative properties against wide range of human cancer cell lines as compared to their respective parent molecules. Furthermore, the C- and O glycosides of Cannabinoids also showed anti-invasive and anti-migratory activities against metastatic cancer cells of breast and pancreatic origin. When applied in combination with DNA damaging agent (5-Fluorouracil) to colorectal cancer cells, the C- and O-glycosides of Cannabinoids potentiate DNA damaging property and thus augment apoptosis resulting in an increment in the efficacy of DNA damaging drugs.

The present application provides a derivative with a repaglinide tetravalent platinum structure and a preparation method and use thereof, the compound with the repaglinide tetravalent platinum structure is shown as general formula (I), wherein, selected from cisplatin or oxaliplatin; L is hydroxyl or a series of repaglinide platinum (IV) compounds targeting p53 pathway described in the present application, which shows good anti-proliferation and anti-metastasis activity in vitro and in vivo. The severe DNA damage caused by platinum core can up-regulate the expression of p53, and repaglinide (RPG) can also effectively promote the secretion of p53 through the lumican / p53 / p21 pathway. The present application designs and synthesizes a series of repaglinide tetravalent platinum derivatives, which can start mitochondrial-mediated apoptosis through the Bcl-2 / Bax / caspase-3 pathway. Subsequently, with the up-regulation of p53, the compound can effectively activate pro-apoptotic autophagy, inhibit the epithelial-mesenchymal transition (EMT) process, and then inhibit tumor angiogenesis by inhibiting COX-2, MMP9 and VEGFA. The compound can also increase the number of CD3 + And CD8 + T cells in tumors by blocking immune checkpoint PD-L1, and stimulate anti-tumor immunity. The above multiple anti-tumor mechanisms synergistically inhibit the proliferation and metastasis of tumor cells.

The application belongs to the technical field of pharmaceutical chemistry, and particularly relates to a naphthalimide-platinum (IV) complex capable of reversing glioma progression based on Lamp2 mediation and application thereof. The application synthesizes a tetravalent platinum-naphthalimide complex with different structures on the two sides of the axis by designing the structure of the compound, so as to realize good activity, low toxicity and antitumor efficacy. The naphthalimide-platinum (IV) complex has high inhibitory activity on tumor cells, and NTCDI-Pt can more effectively inhibit glioma progression compared with cisplatin. The compound NTCDI-Pt has high antitumor activity and anti-metastasis ability in glioma mice, and has high biological safety. The naphthalimide-platinum (IV) complex as a new trend of naphthalimide derivative research has good application prospect by coordinating metal platinum (IV) with naphthalimide to play the mode of its double efficacy.

The invention discloses an application of a miR-1246 inhibitor in preparation of a medicine for preventing or treating postoperative metastasis of hepatocellular carcinoma (HCC). According to the application disclosed by the invention, the expression of miR-1246 in the serum exosome of an HCC patient after operation is obviously up-regulated, the expression of BMP9 protein is inhibited by directly targeting a GDF2 gene, and a downstream SMAD7-mediated metastasis inhibition signal channel is blocked, so that the HCC cell metastasis is driven, that is, the metastasis promoting process can be effectively reversed by inhibiting the function of miR-1246. In-vivo and in-vitro experiments prove that by using the miR-1246 inhibitor, the HCC cell anoikis apoptosis resistance, migration, invasion and in-vivo lung metastasis induced by the serum exosome after operation can be remarkably inhibited. The miR-1246 inhibitor can also be combined with a recombinant protein BMP9 to generate a synergistic anti-metastasis effect. Therefore, the miR-1246 inhibitor provides a new target and strategy for developing a novel anti-HCC postoperative metastasis drug.

The application provides a trifunctional tetravalent platinum compound of captopril-aspirin ligand and a reference drug of a bifunctional tetravalent platinum compound of captopril; and develops a nanomedicine Tf-GEVs@Pt(IV) of the aspirin-captopril trifunctional tetravalent platinum compound loaded in grapefruit extracellular vesicles (GEVs). The Tf-GEVs@Pt(IV) is prepared from the trifunctional tetravalent platinum compound as an active ingredient, the carrier grapefruit extracellular vesicles (GEVs), the carrier DSPE-PEG and the transferrin modified targeting carrier DSPE-PEG-Tf. The Tf-GEVs@Pt(IV) can release the active component trifunctional tetravalent platinum compound in vivo. In addition to causing DNA damage, the trifunctional tetravalent platinum compound as the active component of the nanomedicine can effectively regulate inflammatory, fibrotic and immunosuppressive TME. The nanomedicine has a significant anti-tumor ability and has excellent therapeutic effect on metastatic malignant tumors, and is expected to provide a new candidate drug for clinical treatment of tumors and provide a new direction for research and development of new platinum drugs and anti-metastatic malignant tumor drugs.

The invention belongs to the technical field of nano-drug delivery and stimuli-responsive preparations, and provides a GSH responsive albumin nano-drug as well as a preparation method and application thereof. The method comprises the following steps: connecting albumin with DBCO-PEG2K-NHS, and then carrying out a click reaction with an azido modified RAP peptide, so as to obtain surface functionalized RAP-PEG2K-albumin; then, a disulfide bond in an albumin molecule is reduced by utilizing GSH to generate sulfydryl, paclitaxel and a PADI4 inhibitor GSK484 are added, and then self-assembly is performed to form the nano-drug with a cross-linked disulfide bond. The obtained nano-drug can be quickly disintegrated and released in a tumor cell high-GSH environment, and a Pai-RAGE signal channel is blocked through RAP peptide, so that dual regulation and control of chemotherapy synergy and inhibition of chemotherapy-induced metastasis are realized. The preparation process is mild, no extra cross-linking agent is needed, and the obtained nano-drug has good stability, controllable release characteristic and remarkable anti-tumor and anti-metastasis potential.

Provided are novel peptide compounds containing piperazine acid and stereoisomers, solvates, or pharmaceutically acceptable salts thereof, methods for producing the same, and uses thereof. The peptide compounds and stereoisomers, solvates, or pharmaceutically acceptable salts thereof exhibit anticancer activity, antimetastatic activity, and activity for inhibiting the growth of drug-resistant tumors, and thus can be used for preventing or treating various cancers or cancer metastasis.

The invention relates to the field of biological medicine, in particular to a three-component platinum (IV) complex containing captopril (CTP) and valproic acid (VPA), a preparation method of the three-component platinum (IV) complex and application of the three-component platinum (IV) complex in preparation of anti-tumor proliferation and anti-metastasis drugs. The anti-tumor proliferation and anti-metastasis effects of the target compound are tested through in-vivo and in-vitro testing means, and the anti-tumor mechanism of the medicine is researched. Results prove that the compound has a remarkable anti-tumor capability, particularly has an excellent treatment effect on metastatic malignant tumors, is expected to provide a new candidate drug for clinical treatment of tumors, and provides a new direction for research and development of novel platinum drugs and anti-tumor metastasis drugs.

To provide use of isorhamnetin or pharmaceutically acceptable salts thereof in preparation of drugs for treating esophageal cancer in the technical field of biological medicines.SOLUTION: It has been found that isorhamnetin significantly inhibits malignant growth of metastatic esophageal squamous carcinoma cells and in-vivo ESCC metastatic tumors by inhibiting a fatty acid de novo synthesis pathway in tumor metabolism. Therefore, isorhamnetin can be used for developing an anti-ESCC metastatic cell growth medicine targeting an abnormally active fatty acid de novo anabolic enzyme.SELECTED DRAWING: Figure 1

The present invention relates to a pharmaceutical composition for preventing or treating cancer, and preparation method therefor, the composition comprising a complex of a transdermal permeation peptide and a saccharide, and a lectin. It has been identified that, when the composition comprising the complex of the transdermal permeation peptide and the saccharide, and the lectin is used for cancer treatment, skin permeation of anticancer substances is improved, anti-tumor activity and anti-metastasis properties are exhibited, and hepatotoxicity is not exhibited, and thus effective use as a composition for anticancer treatment is possible.

The present invention comprises synthetic peptides derived from the venom of the H. junceus scorpion with anti-metastatic properties, as well as compositions of synthetic peptides derived from the venom of the H. junceus scorpion and its variants, which are obtained from recombinant or synthesis techniques, with anti-metastatic properties and which are effective against tumour cells or small cell lung cancer cells.

The application belongs to the technical field of anticancer drugs, and particularly relates to an anti-metastasis nano drug and a preparation method and application thereof, and a chemotherapy-light dynamic combined anti-metastasis diagnosis and treatment reagent. The anti-metastasis nano drug provided by the application comprises vitamin E polyethylene glycol succinate nanomicelles, and lauric acid modified tetravalent platinum prodrugs, all-trans retinoic acid and hydrophobic photosensitizers coated in the vitamin E polyethylene glycol succinate nanomicelles. After the anti-metastasis nano drug provided by the application is passively targeted to tumor cells through the EPR effect, the hydrophobic photosensitizer can increase the generation of singlet oxygen under the irradiation of red light, and cooperates with the chemotherapy drug (tetravalent platinum) to achieve the combination of chemotherapy and photodynamic therapy, so that the drug resistance can be overcome and good treatment effect can be achieved. Meanwhile, the anti-metastasis nano drug provided by the application has strong cytotoxicity, exhibits excellent anti-metastasis effect, and can be used for anti-metastasis tumor treatment.

The invention discloses a nano-drug as well as a preparation method and application thereof, and relates to the technical field of biological medicines. The nano-drug provided by the invention comprises nano-particles and an active drug wrapped in the nano-particles, the nanoparticle comprises a carrier and a targeting peptide modified on the surface of the carrier, the active medicine is a hydrophobic BCL-2 protein inhibitor; the carrier comprises a methoxy polyethylene glycol polylactic acid-glycolic acid copolymer; the targeting peptide comprises a cRGD peptide. Based on the important effect of activated platelets in tumor metastasis, the nano-drug provided by the invention adopts a cRGD peptide modified carrier to deliver ABT-737 in a targeted manner, specifically induces apoptosis of the activated platelets, reduces the influence on resting platelets and normal tissues, reduces the toxic and side effects of the drug, significantly inhibits lung metastasis of melanoma, and enhances the anti-metastasis curative effect of a PD-1 antibody; the nano-drug disclosed by the invention can be further expanded to treatment of advanced metastasis of other cancer types except melanoma based on the supporting effect of platelets in various tumor metastasis.

The present invention relates to the medical use of compounds in the treatment of tumor metastasis.

In one aspect, the present disclosure relates to compounds, and methods of use thereof, for reducing and / or inhibiting invasion and / or migration of tumor cells in a subject. In another aspect, the present disclosure relates to compounds, and methods of use thereof, for preventing or at least partially reducing the risk of developing metastatic cancer in a subject. In certain embodiments, the methods described herein comprise administering to the subject at least one Gα12 inhibitor.

The current invention relates to transcription elongation factor eEF1A2-targeted protein degradation ligands and pharmaceutical compositions thereof and their utility as anti-cancer agents.

The application discloses a kind of construction methods, model and system of cancer metastasis organoid model.The method comprises the following steps: preparing tumor cell spheroid labeled with reporter gene and target organ organoid derived from stem cells respectively;It is placed in culture solution;The preset three-dimensional acoustic field is generated using holographic acoustic tweezers, and at least one tumor cell spheroid is moved and positioned at the preset position of target organ organoid by non-contact precise control, to form initial assembly;The initial assembly is maintained in suspension culture, so that it occurs contact, fusion and invasion, to obtain cancer metastasis organoid model.The application uses acoustic force to realize non-destructive, controllable spatial assembly with micron-level precision, and the model constructed can truly reproduce the interaction of tumor cells and target organ cells in three-dimensional environment, to provide a standardized, quantifiable and scalable in-vitro experimental platform for cancer metastasis mechanism research and anti-metastatic drug screening.

The invention discloses an application of combination of KN93 and doxorubicin in prevention and treatment of tumors and tumor metastasis induced by an environmental pollutant PM2.5. Experiments find that KN93 and doxorubicin are combined as active components for use, growth and proliferation of tumors induced by an environmental pollutant PM2.5 can be remarkably inhibited, the number of pulmonary metastasis nodules is remarkably reduced compared with that of a single drug group, and good synergistic anti-tumor and anti-metastasis effects are shown. Therefore, the KN93 and the doxorubicin can be combined to be used for developing the medicine for preventing or treating the PM2.5-induced tumor and tumor metastasis.

The present invention discloses a "copper-dead" nanomaterial, its preparation method, and application. The material is self-assembled from a functional element with copper ion chelation, a functional element with catalytic function, and a functional element that enhances biocompatibility. The "copper-dead" nanomaterial of the present invention has the advantages of a simple preparation process, green economy, low cost, and mass production. It also exhibits excellent anti-tumor and anti-metastasis effects, expanding new treatment options for copper-disordered tumors and providing new insights into tumor treatment. Furthermore, by varying the types of copper-chelating, catalytic, and biocompatibility-enhancing components, as well as the self-assembly method, the material can be extended to the synergistic treatment of other diseases.

The present invention provides a compound having a chloroiodoquine tetravalent platinum structure, a preparation method thereof, and uses thereof. The compound having a chloroiodoquine tetravalent platinum structure is represented by the general formula (I), wherein L1 and L2 are or one of L1 and L2 is and the other is a hydroxyl group. The compound having a chloroiodoquine tetravalent platinum structure according to the present invention has a good therapeutic effect on metastatic malignant tumors, can effectively activate autophagy in tumor cells, and effectively activate the tumor immune response, providing a new direction for the research and development of anti-tumor drugs, especially anti-metastatic malignant tumor drugs.

The present invention provides a derivative having a tetravalent platinum structure of cetirizine, as well as its preparation method and use. The compound having a tetravalent platinum structure of cetirizine is represented by general formula (I), wherein, #imgabs0#, #imgabs1# is selected from cisplatin or oxaliplatin; L is a hydroxyl group or #imgabs2#. The tetravalent platinum structure of cetirizine described in the present invention inhibits histamine (HA) secretion in tumors through the functional group cetirizine, blocks the HA / HRH1 signaling axis, inhibits the PI3K / AKT / mTOR pathway, and thereby inhibits tumor angiogenesis; induces DNA damage through the platinum nucleus; and the two synergistically exert anti-tumor effects. The compound has significant anti-tumor ability, especially excellent therapeutic effects on metastatic malignant tumors. It is expected to provide a new drug candidate for the clinical treatment of tumors and a new direction for the research and development of new platinum drugs and anti-metastatic malignant tumor drugs.